Janus Kinase Inhibition in Granuloma Annulare

Summary

The primary objective is to determine if JAK1 specific inhibition is effective in treating granuloma annulare (GA), a problematic inflammatory skin disease without an FDA approved treatment. The primary outcome will be the percentage change in the body surface area (BSA) involvement by GA after 6 months of treatment with abrocitinib 200 mg daily in 10 patients with moderate to severe GA affecting at least 5% body surface area (BSA).

Timeline

Start

2023-10-27

Primary completion

2024-05-07

Completion

2025-07-01

Drugs

Indications